| |
Departments
of Pharmacology (AP, GG-C, WCS) and Pathology (TJD), The Boyer Center for
Molecular Medicine, Yale University School of Medicine, New Haven, Connecticut;
and Regeneron Pharmaceuticals, Inc. (PCM, GDY), Tarrytown, New York |
| |
Angiopoietin-1 (Ang-1) is a recently described angiogenic protein that
activates the endothelial Tie 2 receptor. Disruption of the Ang-1 gene
shows that it has an indispensable role in blood vessel development, but
it is not clear what specific effects, if any, Ang-1 has on endothelial
cell (EC) phenotypes. Here, we show that Ang-1 dose-dependently stabilizes
HUVEC network organization for up to 48 hours; this action of Ang-1 is
dependent on Tie-2 receptor activation, because a soluble form of the
Tie2-, but not the Tie1-receptor, completely blocks the effects of Ang-1.
Moreover, we show that Ang-1 potentiates the actions of other angiogenic
growth factors. Ang-1 markedly increases the survival of vascular networks
(up to 96 hours) exposed to either vascular endothelial growth factor
or endothelial cell growth supplement, a form of acidic fibroblast growth
factor. In addition, Ang-1 prevents apoptotic death in HUVEC triggered
by withdrawal of endothelial cell growth supplement. Collectively, these
data are consistent with the idea that Ang-1 directly acts on human EC
and interacts with other angiogenic molecules to stabilize vascular structures
by promoting the survival of differentiated ECs.
|